MedTrace Logo

Cognitive Functioning and Health Related Quality of Life in Retinoblastoma Survivors

NCT06227962 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2025-12-04

No results posted yet for this study

Summary

A retrospective crosssectional observational study of the effects of oncological treatment and frequent general anesthesia on neuropsychological development, psychosocial functioning (in terms of anxiety, depression, peer relations, perceived cognitive functioning and potential trauma) and health related quality of life in children and young adults who were treated or screened for retinoblastoma.

Conditions

  • Retinoblastoma
  • Neurocognitive Dysfunction
  • Health-Related Behavior

Interventions

DIAGNOSTIC_TEST

Neuropsychological assesment

Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test

DIAGNOSTIC_TEST

Psychosocial functioning and quality of life (questionnaires)

Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)

DIAGNOSTIC_TEST

Parental psychosocial functioning (questionnaires)

Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)

Sponsors & Collaborators

  • Amsterdam University Medical Center

    lead OTHER

Principal Investigators

  • Annette C. Moll, MD PhD · Amsterdam University Medical Center

Eligibility

Min Age
6 Months
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-26
Primary Completion
2026-10-30
Completion
2028-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06227962 on ClinicalTrials.gov